Genetic Alterations Associated with Sporadic Congenital Hydrocephalus
|
By LabMedica International staff writers Posted on 02 Nov 2020 |

Image: A neural stem cell model of sporadic congenital hydrocephalus (Photo courtesy of Yale University School of Medicine).
Congenital hydrocephalus (CH), characterized by enlarged brain ventricles, is considered a disease of excessive cerebrospinal fluid (CSF) accumulation and thereby treated with neurosurgical CSF diversion with high morbidity and failure rates.
Congenital hydrocephalus is present in the infant prior to birth, meaning the fetus developed hydrocephalus in utero during fetal development. The most common cause of congenital hydrocephalus is aqueductal stenosis, which occurs when the narrow passage between the third and fourth ventricles in the brain is blocked or too narrow to allow sufficient CSF to drain.
A multidisciplinary team at Yale University School of Medicine (New Haven, CT, USA) performed whole-exome sequencing of 381 individuals with sporadic congenital hydrocephalus who were treated with neurosurgery, a cohort that included 232 parent-offspring trios. Another 1,798 trios of unaffected siblings and parents of individuals with autism spectrum disorder were analyzed in parallel as a control group.
The team uncovered 12 genes with two or more de novo mutations each that were predicted to be protein damaging. Five of these genes: TRIM71, SMARCC1, PTEN, PIK3CA, and FOXJ1, had significantly more mutations than expected. The investigators further estimated that about 22% of sporadic congenital hydrocephalus are due to rare, damaging mutations. The teams’ analysis additionally implicated a number of genes in the PI3K signaling pathway in congenital hydrocephalus. These genes regulate cell growth, proliferation, and differentiation in numerous tissues, including developing neural stem cells. In particular, they uncovered three de novo mutations in PI3KCA, three in PTEN, and two in MTOR.
Individuals with mutations in TRIM71, which maintains stem cell pluripotency, are more likely to have cranial nerve defect, non-obstructive inter-hemispheric cysts, and hearing loss. Meanwhile, individuals with mutations in SMARCC1, which regulates gene expression needed for neural stem cell proliferation, differentiation, and survival during telencephalon development, are more likely to have aqueductal stenosis and cardiac and skeletal abnormalities.
All together, the known, high-confidence, and probable risk genes for congenital hydrocephalus converge in gene co-expression networks of the mid-gestational human cortex, In particular, the congenital hydrocephalus risk genes converge on a network previously linked to autism spectrum disorder that is enriched for neuronal differentiation and RNA processing gene ontology terms.
Kristopher T. Kahle, MD, PhD, an assistant professor of neurosurgery and a senior author of the study, said, “It is possible that some of the neurological problems that many of these congenital hydrocephalus patients have may not be due to inadequately working shunts, but are in fact neurodevelopmental sequelae of a genetic condition that alters neuronal function.”
The authors concluded that that genetic disruptions affecting early brain development may drive sporadic congenital hydrocephalus. Their data implicate genetically encoded neural stem cell dysregulation and an associated impairment of fetal neurogliogenesis as primary pathophysiological events in a significant number of congenital hydrocephalus cases. The study was published on October 19, 2020 in the journal Nature Medicine.
Related Links:
Yale University School of Medicine
Congenital hydrocephalus is present in the infant prior to birth, meaning the fetus developed hydrocephalus in utero during fetal development. The most common cause of congenital hydrocephalus is aqueductal stenosis, which occurs when the narrow passage between the third and fourth ventricles in the brain is blocked or too narrow to allow sufficient CSF to drain.
A multidisciplinary team at Yale University School of Medicine (New Haven, CT, USA) performed whole-exome sequencing of 381 individuals with sporadic congenital hydrocephalus who were treated with neurosurgery, a cohort that included 232 parent-offspring trios. Another 1,798 trios of unaffected siblings and parents of individuals with autism spectrum disorder were analyzed in parallel as a control group.
The team uncovered 12 genes with two or more de novo mutations each that were predicted to be protein damaging. Five of these genes: TRIM71, SMARCC1, PTEN, PIK3CA, and FOXJ1, had significantly more mutations than expected. The investigators further estimated that about 22% of sporadic congenital hydrocephalus are due to rare, damaging mutations. The teams’ analysis additionally implicated a number of genes in the PI3K signaling pathway in congenital hydrocephalus. These genes regulate cell growth, proliferation, and differentiation in numerous tissues, including developing neural stem cells. In particular, they uncovered three de novo mutations in PI3KCA, three in PTEN, and two in MTOR.
Individuals with mutations in TRIM71, which maintains stem cell pluripotency, are more likely to have cranial nerve defect, non-obstructive inter-hemispheric cysts, and hearing loss. Meanwhile, individuals with mutations in SMARCC1, which regulates gene expression needed for neural stem cell proliferation, differentiation, and survival during telencephalon development, are more likely to have aqueductal stenosis and cardiac and skeletal abnormalities.
All together, the known, high-confidence, and probable risk genes for congenital hydrocephalus converge in gene co-expression networks of the mid-gestational human cortex, In particular, the congenital hydrocephalus risk genes converge on a network previously linked to autism spectrum disorder that is enriched for neuronal differentiation and RNA processing gene ontology terms.
Kristopher T. Kahle, MD, PhD, an assistant professor of neurosurgery and a senior author of the study, said, “It is possible that some of the neurological problems that many of these congenital hydrocephalus patients have may not be due to inadequately working shunts, but are in fact neurodevelopmental sequelae of a genetic condition that alters neuronal function.”
The authors concluded that that genetic disruptions affecting early brain development may drive sporadic congenital hydrocephalus. Their data implicate genetically encoded neural stem cell dysregulation and an associated impairment of fetal neurogliogenesis as primary pathophysiological events in a significant number of congenital hydrocephalus cases. The study was published on October 19, 2020 in the journal Nature Medicine.
Related Links:
Yale University School of Medicine
Latest Pathology News
- AI-Powered Microscope Diagnoses Malaria in Blood Smears Within Minutes
- Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
- First-Of-Its-Kind Test Identifies Autism Risk at Birth
- AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
- Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
- Fast Label-Free Method Identifies Aggressive Cancer Cells
- New X-Ray Method Promises Advances in Histology
- Single-Cell Profiling Technique Could Guide Early Cancer Detection
- Intraoperative Tumor Histology to Improve Cancer Surgeries
- Rapid Stool Test Could Help Pinpoint IBD Diagnosis
- AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
- Deep Learning–Based Method Improves Cancer Diagnosis
- ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
- New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
- Genetics and AI Improve Diagnosis of Aortic Stenosis
- AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
Channels
Clinical Chemistry
view channel
Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
Acute recreational drug toxicity is a frequent reason for emergency department visits, yet clinicians rarely have access to confirmatory toxicology results in real time. Instead, treatment decisions are... Read more
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
Antibiotic resistance has accelerated into a global health crisis, with projections estimating more than 10 million deaths per year by 2050 as drug-resistant “superbugs” continue to spread.... Read more
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read morePathology
view channel
AI-Powered Microscope Diagnoses Malaria in Blood Smears Within Minutes
Malaria remains one of the world’s deadliest infectious diseases, killing hundreds of thousands each year, mostly in under-resourced regions where laboratory infrastructure is limited. Diagnosis still... Read more
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read moreNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more







